/
Neurology
Amyotrophic Lateral Sclerosis
56
Pipeline Programs↗
89
Active Trials↗
69
Companies Involved↗
Amyotrophic Lateral Sclerosis is a moderately active landscape with 56 programs across 69 companies. The most active players are Amylyx Pharmaceuticals Inc., Biogen, Ionis Pharmaceuticals. 6 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical22
Phase 113
Phase 215
Phase 36
Approved
No programs
Analysis
Modality Breakdown
98%
Small molecule
42 of 43 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 43 classified programs, each share of the total. Modality classified for 86% of 56 pipeline programs.
Analysis
Trial Status
295
clinical trials
Completed142 · 48%
Recruiting42 · 14%
Terminated29 · 10%
Active, not recruiting24 · 8%
Not yet recruiting20 · 7%
Unknown status17 · 6%
Other21 · 7%
Clinical Trials
Trial Activity
295 trials
Page 1 of 20
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)